Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay M Edelberg

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Journal of the American College of Cardiology|May 30, 2020
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyCarolyn Y Ho, Matthew E Mealiffe, Richard G Bach, et al.
Journal of the American College of Cardiology|January 18, 2020
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary SyndromeVera A Bittner, Michael Szarek, Philip E Aylward, et al.
Journal of the American College of Cardiology|November 15, 2018
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES TrialMichael Szarek, Harvey D White, Gregory G Schwartz, et al.
Lancet (London, England)|September 2, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology|November 11, 2025
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label TrialNeal K Lakdawala, Ray E Hershberger, Pablo Garcia-Pavia, et al.
European Journal of Heart Failure|June 20, 2020
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trialAdriaan A Voors, Jean-François Tamby, John G Cleland, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 2004
Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient miceMark Veugelers, David Wilkes, Kimberly Burton, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Journal of the American College of Cardiology|May 30, 2020
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic CardiomyopathyCarolyn Y Ho, Matthew E Mealiffe, Richard G Bach, et al.
Journal of the American College of Cardiology|January 18, 2020
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary SyndromeVera A Bittner, Michael Szarek, Philip E Aylward, et al.
Journal of the American College of Cardiology|November 15, 2018
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES TrialMichael Szarek, Harvey D White, Gregory G Schwartz, et al.
Lancet (London, England)|September 2, 2020
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology|November 11, 2025
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label TrialNeal K Lakdawala, Ray E Hershberger, Pablo Garcia-Pavia, et al.
European Journal of Heart Failure|June 20, 2020
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trialAdriaan A Voors, Jean-François Tamby, John G Cleland, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 17, 2004
Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient miceMark Veugelers, David Wilkes, Kimberly Burton, et al.
Pageof 6